RecruitingPhase 1NCT07446101

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants

Sponsor

Eli Lilly and Company

Enrollment

450 participants

Start Date

Mar 24, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria8

Are overtly healthy males or females as determined by medical evaluation including:
medical history
physical examination
clinical laboratory tests
ECG, and
vital signs.
Have clinical laboratory test results at screening and Day -1 within normal reference range.
Have a body mass index (BMI) within the range of 18.0 to 34.0 kilograms per square meter (kg/m²), inclusive.

Exclusion Criteria11

Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy.
Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs.
Have clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions.
Are immunocompromised.
Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing.
Have received treatment with biologic agents within 3 months or 5 half-lives, whichever is longer, prior to dosing.
Have previously received mirikizumab.
Have an abnormality in the 12-lead electrocardiogram (ECG).
Have clinically significant abnormalities in blood pressure, pulse rate, or body temperature.
Have a current or recent acute, active infection.
Have active tuberculosis (TB), or any history of active TB.